The effects of calcium channel blockers on cardiovascular outcomes: A review of randomised controlled trials

Blood Pressure

Volumn 11, Issue 2, 2002, Pages 71-78

  De Leeuw, Peter W ^a   Birkenhäger, Willem H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Calcium channel blockers; Hypertension; Randomised controlled trials

Indexed keywords

AMILORIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; LONG ACTING DRUG; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; NORDIL; PINDOLOL; PLACEBO; TRICHLORMETHIAZIDE; VERAPAMIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIURESIS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; METABOLIC DISORDER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; TREATMENT PLANNING; OUTCOME ASSESSMENT;

CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMAN; HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; DIABETES COMPLICATIONS; HUMANS;

EID: 0035988499     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050211260     Document Type: Review

References (39)

1. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
2. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
3. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points
4. Diuretics vs alpha-blockers for treatment of hypertension: Lessons from ALLHAT. Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial
5. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators
6. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL)
7. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial
8. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives
9. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
10. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
11. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators
12. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
13. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
14. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
15. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
16. Shanghai trial of nifedipine in the elderly (STONE)
17. Statistics notes. Treatment allocation in controlled trials: Why randomise?
18. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes
19. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics
20. Arterial calcification and calcium antagonists: What does it mean?
21. INSIGHT and NORDIL
22. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
23. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
24. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials
25. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis
26. Why do we need some large, simple randomized trials?
27. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
28. British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity
29. Management of hypertension. Evidence shows that calcium antagonists reduce cardiovascular end points in diabetic patients
30. Calcium channel blockers in diabetic subjects: Innocent at last?
31. Diabetes and cardiovascular events in hypertensive patients
32. Hypertension trials: 1990 to 2000
33. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT)
34. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
35. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
36. An exercise in mega-silliness
37. Statistician with a mission
38. Blood-pressure-lowering treatment
39. Blood-pressure-lowering treatment